Previous 10 | Next 10 |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on January 18, 2024 at the virtual B. Riley Securities 4 ...
2023-12-14 01:41:25 ET Summary Puma Biotechnology is a commercial-stage biotech with a struggling approved drug, neratinib, but potential for gains. The company is focused on refining current indications for neratinib and investigating dose optimization. Puma Biotechnology's g...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer (PUMA-ALI-1201). Based on the Company’s interacti...
2023-11-13 08:32:18 ET Tivic Health Systems Inc ( TIVC ) +108% . Collective Audience Inc ( CAUD ) +35% . FREYR Battery ( FREY ) +17% Publishes Shareholder Letter. RLX Technology Inc ADR ( RLX ) +12% Q3 earnings call release Babcock &...
2023-11-02 22:21:06 ET Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Conference Call November 02, 2023, 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - Chairman, President and CEO Maximo Nougues - CFO Jeff Ludwig - ...
2023-11-02 16:58:49 ET Puma Biotechnology press release ( NASDAQ: PBYI ): Q3 Non-GAAP EPS of $0.17 beats by $0.03 . Revenue of $56.1M (-1.8% Y/Y) misses by $1.85M . Fourth Quarter and Full Year 2023 Financial Outlook For further details see: P...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022. Product revenue, net consists ent...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Puma Biotechnology Inc (PBYI) is expected to report $0.08 for Q3 2023
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 2, 2023, following the release of its third quarter 2023 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug Application (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib fo...
Evolv Technologies Holdings Inc. (EVLV) is expected to report $-0.14 for Q4 2023 The Lion Electric Company (LEV) is expected to report $-0.1 for Q4 2023 Fisker Inc. Class A (FSR) is expected to report $-0.2 for Q4 2023 Y-mAbs Therapeutics Inc. (YMAB) is expected to report $-0.19 for Q...